Evidence map›Paper›PMID 39339931›Full record

Trial reportViruses2024

Harm Reduction in Peer-Assisted Telemedicine for Hepatitis C: Secondary Outcomes of a Randomized Controlled Trial.

Hunter Spencer, Devin Gregoire, Gillian Leichtling, Megan Herink, Andrew Seaman, P Todd Korthuis, Ryan Cook

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hunter SpencerDivision of General Internal Medicine & Geriatrics, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0002-5710-1836
Devin GregoireDivision of General Internal Medicine & Geriatrics, Oregon Health & Science University, Portland, OR 97239, USA.
Gillian LeichtlingComagine Health, Portland, OR 97232, USA.ORCID 0000-0003-4936-1379
Megan HerinkCollege of Pharmacy, Oregon State University, Corvallis, OR 97331, USA.ORCID 0000-0001-6402-0260
Andrew SeamanDivision of General Internal Medicine & Geriatrics, Oregon Health & Science University, Portland, OR 97239, USA.
P Todd KorthuisDivision of General Internal Medicine & Geriatrics, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0001-5556-3597
Ryan CookDivision of General Internal Medicine & Geriatrics, Oregon Health & Science University, Portland, OR 97239, USA.

Funding

Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Oregon Clinical and Translational Research Institute KL2 SupplementKL2TR002370 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Catherine Lee Hough · 2017 to 2026
$10.1M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
Transporting treatment effects from clinical trials to real-world populations with co-occurring opioid and stimulant use disordersK01DA055130 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI COOK, RYAN · 2022 to 2025
$714k
NCATS NIH HHS KL2 TR002370NIDA NIH HHS K01 DA055130NIDA NIH HHS UG1 DA015815NIDA NIH HHS UH3 DA044831NIH HHS UG1DA015815NIH HHS UH3DA044831
6 · The paper itself

Abstract

Hepatitis C (HCV) treatment for people who use drugs (PWUD) decreases injection drug use and injection equipment sharing. We examined changes in injection drug use and injection equipment sharing following HCV treatment in a randomized trial comparing peer-assisted telemedicine for HCV treatment (TeleHCV) versus peer-assisted usual care in rural PWUD. We hypothesize that TeleHCV reduces risky behaviors and peers facilitate this change. We used mixed-effects logistic regression to describe participant-level (

Indexed as

Harm ReductionHepatitis CPeer GroupSubstance Abuse, IntravenousTelemedicineAdultFemaleHumansMaleMiddle AgedNeedle SharingRisk-Takingharm reductionhepatitis C virus (HCV)people who use drugs (PWUD)

Identifiers

PMID39339931
PMCPMC11437492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.